Accessibility Menu
Sera Prognostics logo

Sera Prognostics(NASDAQ) SERA

Current Price$2.23
Market Cap$82.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-83%
5 Year-79%
1 Year-28%
1 Month+20%
Sera Prognostics last closing stock price
MetricPriceDate
Last closeUSD 2.102026-07-20
Sera Prognostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.38%USD 1.922026-07-13
1 month+20%USD 1.752026-06-18
3 month-3.23%USD 2.172026-04-21
Year to date-28.81%USD 2.952025-12-31
1 year-28.08%USD 2.922025-07-18
3 year-33.54%USD 3.162023-07-21
5 year-78.89%USD 9.952021-07-21
Since inception-82.77%USD 11.902021-07-15

Sera Prognostics Financials at a Glance

Market Cap

$82.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$57.00K

Net Income (TTM)

-$32.14M

EPS (TTM)

-$0.65

P/E Ratio

-3.25

Dividend

$0.00

Beta (Volatility)

0.86 (Low)

Price

$2.23

Volume

4,251

Open

$2.09

Previous Close

$2.10

Daily Range

$2.09 - $2.23

52-Week Range

$1.56 - $3.95

Estimated Earnings Date

Aug 5, 2026

SERA News

Foolcom-Featured.png

Sera Prognostics (SERA) Q2 Loss Down 4%

Motley Fool Markets TeamAug 7, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sera Prognostics

Sera Prognostics helps doctors predict pregnancy risks with simple blood tests. Its main product, PreTRM, identifies women at risk for early birth. This helps healthcare providers plan care and reduce complications for mothers and babies.

Products and Services

  • PreTRM Test: Blood test predicting risk of early birth in single pregnancies; currently comprises substantially all revenue.
  • Pregnancy Risk Panel: In development, aims to identify high-risk pregnancies for various complications.
  • LikeMine Webapp: Digital tool offering personalized pregnancy risk information for patients and providers.
  • Biomarker Pipeline: Tests in development for preeclampsia, gestational diabetes, fetal growth issues, and postpartum depression.
  • Proprietary Analytics Platform: Uses advanced lab techniques and artificial intelligence to analyze blood samples.

Growth and Expansion

  • Launched PreTRM test in the U.S. market; no international expansion to date.
  • Expanded commercial partnership activities with Elevance Health in 2025 to support test adoption.
  • Published PRIME study results in January 2026, supporting clinical outcomes for PreTRM.
  • Expanded commercial and medical leadership teams in 2025 to support growth.
  • Developed and beta-tested the LikeMine webapp for broader consumer engagement in 2025.

What Makes Sera Prognostics Stand Out

Sera Prognostics relies on a proprietary technology platform and a large, diverse biobank of blood samples. Its focus on clinical validation and health economics sets it apart in pregnancy diagnostics. The company’s collaboration with Elevance Health supports broader access to its core test.

Five Things You Need to Know

  • Revenue was $16,000 in Q3 2025, down 44.8% from Q3 2024.
  • Net loss was $31.9 million in FY2025, a 3% improvement from FY2024.
  • All revenue comes from the PreTRM test; no international sales reported.
  • Cash and marketable securities totaled $95.8 million as of December 31, 2025.
  • Collaboration with Elevance Health is key for commercial adoption and revenue concentration.

Bottom Line

Sera Prognostics focuses on predictive pregnancy diagnostics with a single main product and ongoing development pipeline. The company faces financial challenges but continues to invest in innovation and strategic partnerships.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

72

CEO

Evguenia Lindgardt, MBA

Website

www.seraprognostics.com

Headquarters

Salt Lake City, UT 84109, US

SERA Financials

Key Financial Metrics (TTM)

Gross Margin

-191.23%

Operating Margin

-64235.09%

Net Income Margin

-56385.96%

Return on Equity

-41.02%

Return on Capital

-46.95%

Return on Assets

-34.36%

Earnings Yield

-30.77%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$82.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

39.16M

Volume

4.25K

Avg. Volume

50.97K

Financials (TTM)

Gross Profit

-$109.00K

Operating Income

-$36.61M

EBITDA

-$31.22M

Operating Cash Flow

-$26.84M

Capital Expenditure

-$731.00K

Free Cash Flow

-$27.58M

Cash & ST Invst.

$47.40M

Total Debt

$2.51M

Sera Prognostics Performance Analysis

Sera Prognostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 268,000226.8%
20232023-12-31USD 306,00014.2%
20242024-12-31USD 77,000-74.8%
20252025-12-31USD 81,0005.2%
Sera Prognostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-55.3%
Q32025-09-30-5.9%
Q42025-12-31-37.5%
Q12026-03-3140.0%
Sera Prognostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.4325.5%
20232023-12-31USD -1.16-18.7%
20242024-12-31USD -0.99-14.6%
20252025-12-31USD -0.67-32.5%
Sera Prognostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3020.0%
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-6.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$14.00K

-63.2%

Gross Profit

-$28.00K

-1300.0%

Gross Margin

-2.00%

N/A

Market Cap

$82.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.31M

N/A

Employees

63

N/A

Net Income

-$8.40M

-2.6%

EBITDA

-$8.20M

-3.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$47.40M

+2.6%

Total Debt

$2.51M

+341.0%

Accounts Receivable

$11.00K

-56.0%

Inventory

$0.00

N/A

Long Term Debt

$2.51M

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-34.36%

N/A

Return on Invested Capital

-52.21%

N/A

Free Cash Flow

-$8.78M

-16.2%

Operating Cash Flow

-$8.77M

-16.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ONCYOncolytics Biotech Inc.
$0.83-2.05%
CGTXCognition Therapeutics, Inc.
$0.98+3.20%
RPIDRapid Micro Biosystems, Inc.
$2.07+0.24%
LUCDLucid Diagnostics Inc.
$0.98+0.72%

Trending Stocks

Symbol / CompanyPricePrice Chg
VIVKVivakor
$5.49+2.17%
UTZUtz Brands
$14.12+0.89%
AALAmerican Airlines Group
$15.28+0.01%
SOFISoFi Technologies
$17.44+0.02%

Questions About SERA

What is the current price of Sera Prognostics?

Sera Prognostics is trading at $2.23 per share.

What is the 52-week range for Sera Prognostics?

Over the past 52 weeks, Sera Prognostics has traded between $1.56 and $3.95.

How much debt does Sera Prognostics have?

As of the most recent reporting period, Sera Prognostics reported total debt of $2.51M.

How much cash does Sera Prognostics have on hand?

Sera Prognostics reported $4.18M in cash and cash equivalents in its most recent financial results.

What is Sera Prognostics’s dividend yield?

Sera Prognostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services